Pearl was founded in 2006, with a mission to develop differentiated therapeutics for respiratory disease conditions prevalent worldwide, including chronic obstructive pulmonary disease (COPD). The product candidates currently being developed are based on the simple and widely prescribed
Pearl has an experienced team of inhalation product development experts with proven track record in the development and commercialization of innovative respiratory products. Pearl’s lead product candidates are a